Table 1.
Patient characteristics at baseline.
| ADT (n=101) | No ADT (n=196) | p-value | |
|---|---|---|---|
| Age at Surgery, median (IQR) | 66 (59 – 72) | 65 (58 – 70) | 0.1 |
| Race, n (%) | |||
| Caucasian | 81 (80.2%) | 158 (80.6%) | 0.6 |
| Black | 6 (5.9%) | 8 (4.1%) | |
| Asian | 7 (6.9%) | 9 (4.6%) | |
| Hispanic | 5 (5.0%) | 18 (9.2%) | |
| Other | 2 (2.0%) | 3 (1.5%) | |
| BMI, median (IQR) | 27.1 (25.0 – 31.0) | 27.5 (24.9 – 30.4) | 0.7 |
| PSA, median (IQR)/n (%) | 8.0 (4.9 – 13.0) | 7.2 (5.1 – 12.7) | 1.0 |
| ≤10 | 65 (64.4%) | 128 (65.3%) | 1.0 |
| 10–20 | 26 (25.7%) | 50 (25.5%) | |
| >20 | 10 (9.9%) | 18 (9.2%) | |
| Total CCI, median (IQR) | 2 (2 – 3) | 2 (2 – 8) | 0.08 |
| Total CCI - Age Adjusted, median (IQR) | 5 (4 – 6) | 5 (4 – 9) | 0.3 |
| ADT Duration >3 months – all patients, n (%)– high-risk patients, n (%) | 36 (36%) 12 (40%) | ||
| Pre-Operative Gleason Score, n (%) | |||
| ≤6 | 33 (32.7%) | 66 (33.7%) | 0.9 |
| 7 | 44 (43.6%) | 87 (44.4%) | |
| ≥8 | 24 (23.8%) | 43 (21.9%) | |
| Clinical T Stage, n (%) | |||
| T1 | 74 (73.3%) | 146 (74.5%) | 0.4 |
| T2 | 26 (25.7%) | 50 (25.5%) | |
| T3 | 1 (1.0%) | 0 (0.0%) | |
| Damico Risk group, n (%) | |||
| Low | 21 (20.8%) | 42 (21.4%) | 1.0 |
| Intermediate | 50 (49.5%) | 97 (49.5%) | |
| High | 30 (29.7%) | 57 (29.1%) |